Thienodibenzoazulene compounds as tumor necrosis factor inhibitors
US6897211B2 · kind B2 · utility
0Cited by
0References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 18, 2002 |
| Grant date | May 24, 2005 |
| Priority date | — |
| Expiry date | Nov 18, 2022 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the dibenzoazulene compounds represented by formula I as well as to their pharmaceutical preparations for the inhibition of tumor necrosis factor alpha (TNF-α) and interleukine 1 (IL-1) in mammals at all diseases and conditions where these mediators are excessively secreted. The compounds of the present invention also demonstrate an analgetic action and can be used to relieve pain.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.